Search
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170] … [A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Nelfinavir
go.drugbank.com/drugs/DB00220ApprovedInvestigationalNelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.[L36485] … It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalThese receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Etodolac
go.drugbank.com/drugs/DB00749ApprovedInvestigationalVet approvedIts therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Mixtures: NuDroxiPAK E-400Products: LODINE CAPSULAS DE 300 MGEthosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
go.drugbank.com/drugs/DB16902ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16903ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16910ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16914ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.